Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;84(3):473-88.
doi: 10.4269/ajtmh.2011.10-0521.

Health economics of dengue: a systematic literature review and expert panel's assessment

Mark E Beatty  1 , Philippe Beutels, Martin I Meltzer, Donald S Shepard, Joachim Hombach, Raymond Hutubessy, Damien Dessis, Laurent Coudeville, Benoit Dervaux, Ole Wichmann, Harold S Margolis, Joel N Kuritsky
Affiliations

Health economics of dengue: a systematic literature review and expert panel's assessment

Mark E Beatty et al. Am J Trop Med Hyg. 2011 Mar.

Abstract

Dengue vaccines are currently in development and policymakers need appropriate economic studies to determine their potential financial and public health impact. We searched five databases (PubMed, EMBASE, LILAC, EconLit, and WHOLIS) to identify health economics studies of dengue. Forty-three manuscripts were identified that provided primary data: 32 report economic burden of dengue and nine are comparative economic analyses assessing various interventions. The remaining two were a willingness-to-pay study and a policymaker survey. An expert panel reviewed the existing dengue economic literature and recommended future research to fill information gaps. Although dengue is an important vector-borne disease, the economic literature is relatively sparse and results have often been conflicting because of use of inconsistent assumptions. Health economic research specific to dengue is urgently needed to ensure informed decision making on the various options for controlling and preventing this disease.

PubMed Disclaimer

Conflict of interest statement

Disclosure: LC is an employee of Sanofi Pasteur, a company that is currently developing a dengue vaccine. This statement is made in the interest of full disclosure and not because the authors consider this to be a conflict of interest.

Figures

Figure 1.
Figure 1.
Results of systematic literature search and evaluation of identified studies.
See this image and copyright information in PMC

References

    1. Scientific Working Group on Dengue . Report of the Scientific Working Group on Dengue, 1–5 October 2006. Geneva: World Health Organization; 2007.
    1. Gubler DJ, Clark GG. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis. 1995;1:55–57. - PMC - PubMed
    1. Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, Chambonneau L, Morrisson DN, Shaw D, Qiao M, Dumas R, Lang J, Forrat R. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 2008;26:5712–5721. - PubMed
    1. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccine. 2008;4:33–40. - PubMed
    1. Widdus R. Public-private partnerships: an overview. Trans R Soc Trop Med Hyg. 2005;99((Suppl 1)):S1–S8. - PubMed

Publication types

Substances